Role of STARD6 in ovarian steroidogenesis
Role of STARD6 in ovarian steroidogenesis
批准号:
8514023
负责人:
HOLLY ANNE LAVOIE
金额:
$6.5万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2015-07-31
关键词:
Adrenal GlandsBindingCell Culture TechniquesCell DeathCellsCellular MembraneCholesterolCyclic AMPDataDiseaseEstrogensEtiologyFamilyFamily suidaeFeedbackFemaleFutureGenesGlucocorticoidsGoalsGonadal Steroid HormonesGraafian FolliclesGrowth FactorHealth Care CostsHormonalHormonesHumanHypothalamic structureIn VitroIndividualInfertilityLaboratoriesLifeLipidsLipoid congenital adrenal hyperplasiaLipoproteinsLongevityLow-Density LipoproteinsLuteinizing HormoneMeasuresMediatingMenstrual cycleMenstruation DisturbancesMessenger RNAMineralocorticoidsMitochondriaMovementMusNorthern BlottingOvarianOvarian DiseasesOvarian Steroid HormoneOvaryOvulationOvumPeriodicityPhasePlasmaPopulationPregnancyPregnancy MaintenancePreparationProductionProgesteroneProteinsRecombinantsReplacement TherapyRoleSideSignal TransductionSomatomedinsSteroid biosynthesisSteroidsStructureTertiary Protein StructureTestingTestisTimeTissuesTranscriptUterusWomanbasecell typecholesterol traffickingcorpus luteumdefined contributionfallsgranulosa cellimplantationinsightleydig interstitial cellmemberneuronal cell bodynoveloverexpressionprotein structurereproductivesmall hairpin RNAsteroidogenic acute regulatory proteintheca cell
中文摘要
描述(申请人提供):在女性,孕酮是正常月经周期和维持妊娠所必需的。除了为排卵准备卵子外,卵巢的另一个关键功能是从胆固醇合成新的类固醇。类固醇的合成主要发生在黄体生成素(LH)激增之前的卵泡膜细胞层和黄体细胞中。与卵泡相比,黄体表现出新的类固醇合成的显著增加。起始结构域蛋白STARD1(类固醇合成急性调节蛋白)介导类固醇合成的限速步骤,即胆固醇从外到内线粒体的运输,在那里发生了新的类固醇合成的第一个酶步骤。有体外证据表明,一种新的起始结构域蛋白STARD6可以发挥与STARD1相似的功能。此前,其他实验室的两项初步研究未能在卵巢中检测到STARD6。利用基因芯片技术,我们偶然在黄体形成的猪颗粒细胞中发现了STARD6的mRNA,并进一步发现它在黄体中期高表达,黄体是一个高水平的组织,孕酮的合成也很高。我们的长期目标是更好地了解胆固醇在卵巢中的运输,因为它与正常的卵巢功能和卵巢疾病的治疗有关。这项建议的主要目的是确定STARD6在人卵巢细胞中对卵巢新生类固醇合成的贡献。在目标1中,我们将确定STARD6是否定位于人卵巢的类固醇生成细胞。将对人类卵巢切片进行探测,以确定表达STARD6的细胞群体,并将评估结构中的mRNA和蛋白质水平。目的2将验证两个假设,即STARD6以STARD1非依赖或STARD1依赖的方式在人黄体颗粒细胞中介导类固醇的生成。这些研究将利用shRNA过表达STARD6和敲除STARD6来评估对类固醇合成的影响。目的3验证STARD6与黄体化颗粒细胞胆固醇室的假设,并在激素合成活跃的条件下改变其在室间的分布。这些研究将确定STARD6在细胞内的定位,并确定在基础条件和cAMP刺激条件下,当细胞补充低密度脂蛋白(LDL)时,STARD6是否发生动员。目的4将验证STARD6基因和蛋白在黄体化颗粒细胞中受特定的非促性腺激素或生长因子调节的假设。原代培养的人黄体颗粒细胞将被胰岛素样生长因子和其他候选调节剂处理,以确定STARD6的mRNA和蛋白是否发生改变。该项目的成功完成将为卵巢类固醇生成的胆固醇运输提供新的见解,并将作为未来研究的基础。
卵巢异常的类固醇激素生成障碍。
英文摘要
DESCRIPTION (provided by applicant): In females, progesterone is needed for normal menstrual cyclicity and for the maintenance of pregnancy. In addition to preparation of the ovum for ovulation, another critical function of the ovary is de novo steroid synthesis from cholesterol De novo steroidogenesis occurs predominantly in the theca cell layer of the follicle prior to the luteinizing hormone (LH) surge and in the cells of the corpus luteum following the LH surge. The corpus luteum demonstrates a dramatic increase in de novo steroidogenesis compared to the follicle. A START domain protein STARD1 (steroidogenic acute regulatory protein) mediates the rate-limiting step in steroidogenesis, the transport of cholesterol from the outer to the inner mitochondrion, where the first enzymatic steps in de novo steroidogenesis occur. There is in vitro evidence that a novel START domain protein, STARD6, can function similarly to STARD1. Two preliminary studies by other laboratories previously failed to detect STARD6 in the ovary. Using microarray, we serendipitously found STARD6 mRNA in luteinizing pig granulosa cells and further found it to be highly expressed in midluteal phase corpora lutea, a tissue with high STARD1 levels and high progesterone synthesis. Our long-term goal is to better understand cholesterol trafficking in the ovary as it relates to normal ovarian function and the treatment of ovarian disorders. The main goal of this proposal is to define the contribution of STARD6 to ovarian de novo steroidogenesis in human ovarian cells. In Aim 1, we will determine if STARD6 is localized to steroidogenic cells of human ovaries. Sections of human ovaries will be probed to determine the cell populations expressing STARD6 and mRNA and protein levels will be assessed in structures. Aim 2 will test two sub-hypotheses that STARD6 mediates steroidogenesis in either a STARD1-independent or STARD1-dependent manner in human luteinized granulosa cells. These studies will overexpress STARD6 and knockdown STARD6 using shRNA to evaluate effects on steroidogenesis. Aim 3 will test the hypothesis that STARD6 is associated with cholesterol compartments in luteinized granulosa cells and changes its distribution between compartments under conditions of active steroid synthesis. These studies will determine the localization of STARD6 to intracellular compartments and determine if mobilization of STARD6 occurs when cells are supplemented with low density lipoproteins (LDL) under basal and cAMP-stimulated conditions. Aim 4 will test the hypothesis that STARD6 mRNA and protein are regulated by specific non-gonadotropin hormones or growth factors in luteinized granulosa cells. Primary cultures of human luteinized granulosa cells will be treated with insulin-like growth factors and other candidate regulators to determine if STARD6 mRNA and protein are altered. Successful completion of this project will provide new insight into cholesterol trafficking for ovarian steroidogenesis and will serve as a basis for future studies of
disorders of aberrant steroidogenesis by the ovary.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of STARD6 in ovarian steroidogenesis
-
批准号:8384654
-
项目类别:
-
资助金额:$6.85万
-
财政年份:2012
-
负责人:HOLLY ANNE LAVOIE
-
依托单位:
OVARIAN LDL RECEPTOR AND STAR GENE REGULATION
-
批准号:6603240
-
项目类别:
-
资助金额:$14.18万
-
财政年份:1999
-
负责人:HOLLY ANNE LAVOIE
-
依托单位:
OVARIAN LDL RECEPTOR AND STAR GENE REGULATION
-
批准号:2908599
-
项目类别:
-
资助金额:$12.6万
-
财政年份:1999
-
负责人:HOLLY ANNE LAVOIE
-
依托单位:
OVARIAN LDL RECEPTOR AND STAR GENE REGULATION
-
批准号:6182360
-
项目类别:
-
资助金额:$12.97万
-
财政年份:1999
-
负责人:HOLLY ANNE LAVOIE
-
依托单位:
OVARIAN LDL RECEPTOR AND STAR GENE REGULATION
-
批准号:6536133
-
项目类别:
-
资助金额:$13.76万
-
财政年份:1999
-
负责人:HOLLY ANNE LAVOIE
-
依托单位:
OVARIAN LDL RECEPTOR AND STAR GENE REGULATION
-
批准号:6387726
-
项目类别:
-
资助金额:$13.36万
-
财政年份:1999
-
负责人:HOLLY ANNE LAVOIE
-
依托单位:
MECHANISMS OF OVARIAN CELL LDL RECEPTOR GENE EXPRESSION
-
批准号:2196451
-
项目类别:
-
资助金额:$2.86万
-
财政年份:1996
-
负责人:HOLLY ANNE LAVOIE
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: